Glycine serum level in schizophrenia: Relation to negative symptoms

Psychiatry Research

Volumn 176, Issue 2-3, 2010, Pages 103-108

  Hons, Jaromir ^a   Zirko, Rastislav ^b   Ulrychova, Martina ^b   Cermakova, Eva ^c   Doubek, Pavel ^c   Libiger, Jan ^b  

^a REGIONAL HOSPITAL LIBEREC   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Excitatory amino acids; Glycine; Negative symptoms; NMDA receptor; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE DECANOATE; GLYCINE; HALOPERIDOL; HALOPERIDOL DECANOATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; DISEASE DURATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATHOGENESIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM;

ADULT; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLYCINE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEX FACTORS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 77949774877     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.11.008     Document Type: Article

References (49)

1. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry, Supplement 1989, 7:49-58.
2. Baruah S., Waziri R., Sherman A. Neuroleptic effects on serine and glycine metabolism. Biological Psychiatry 1993, 34:544-550.
3. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry 2007, 164(10):1593-1602.
4. Carl G.F., Brogan M.P., Young B.K. Is plasma serine a marker for psychosis?. Biological Psychiatry 1992, 31:1130-1135.
5. Evins A.E., Fitzgerald S.M., Wine L., Rosselli R., Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. American Journal of Psychiatry 2000, 157:826-828.
6. Evins A.E., Amico E., Posever T.A., Toker R., Goff D.C. d-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Research 2002, 56(1-2):19-23.
7. Friedman M. Chemistry, nutrition, and microbiology of d-amino acids. Journal of Agricultural and Food Chemistry 1999, 47:3457-3479.
8. Fuchs S.A., De Barse M.M., Scheepers F.E., Cahn W., Dorland L., de Sain-van der Velden M.G., Klomp L.W., Berger R., Kahn R.S., de Koning T.J. Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. European Neuropsychopharmacology 2008, 18(5):333-338.
9. Goff D.C., Evins A.E. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harvard Review of Psychiatry 1998, 6:59-77.
10. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. A dose-finding trial of d-cycloserine added to neuroleptic for negative symptoms in schizophrenia. American Journal of Psychiatry 1995, 152:1213-1215.
11. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. d-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry 1996, 153(12):1628-1630.
12. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D.S., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 1999, 56(1):21-27.
13. Harvey P.D., Putnam K.M., Davidson M., Kahn R.S., Powchik P., McQueeney R., et al. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Research 1991, 38:285-292.
14. Hashimoto A., Oka T. Free d-aspartate and d-serine in the mammalian brain and periphery. Progress in Neurobiology 1997, 52:325-353.
15. Henderson G., Johnson J.W., Ascher P. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-d-aspartate receptor. Journal of Physiology (London) 1990, 430:189-212.
16. Heresco-Levy U., Javitt D.C. Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophenia: a retrospective analysis. Schizophrenia Research 2004, 66(2-3):89-96.
17. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 1996, 169:610-617.
18. Heresco-Levy U., Javitt D.C., Ermilov M., Silipo G., Shimoni J. Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology 1998, 1(2):131-135.
19. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 1999, 56(1):29-36.
20. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. American Journal of Psychiatry 2002, 159(3):480-482.
21. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry 2004, 55(2):165-171.
22. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 2005, 57(6):577-585.
23. Heresco-Levy U., Bar G., Levin R., Ermilov M., Ebstein R.P., Javitt D.C. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophrenia Research 2007, 91:14-21.
24. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 1994, 151:1234-1236.
25. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., Lindenmayer J.P., Suckow R., Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2001, 4(4):385-391.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
27. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin 2006, 32:214-219.
28. Korpi E.R., Kaufmann C.A., Marnela K., Weinberger D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Research 1987, 20:337-345.
29. Kutlan D., Molnar-Perl I. New aspects of the simultaneous analysis of amino acids and amines as their o-phthaldialdehyde derivatives by high-performance liquid chromatography. Analysis of wine, beer and vinegar. Journal of Chromatography 2003, 987:311-322.
30. Kutlan D., Presits P., Molnar-Perl I. Behavior and characteristics of amine derivatives obtained with o-phthaldialdehyde/3-mercaptopropionic acid and with o-phthaldialdehyde/N-acetyl-cysteine reagents. Journal of Chromatography 2002, 949:235-248.
31. Lane H., Chang Y., Liu Y., Chiu Ch., Tsai G. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia. Archives of General Psychiatry 2005, 62:1196-1204.
32. Lane H., Huang Ch., Wu P., Liu Y., Chang Y., Lin P., Chen P., Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological Psychiatry 2006, 60(6):645-649.
33. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Research 1990, 32:63-70.
34. Miller D.D., Flaum M., Arndt S., Fleming F., Andreasen N.C. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 1994, 11:11-20.
35. Möller H.J., Van Praag H.M., Aufdembrinke B., Bailey P., Barnes T.R.E., Beck J., et al. Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology 1994, 115:221-228.
36. Molnar-Perl I. Quantification of amino acids and amines in the same matrix by high-performance liquid chromatography, either simultaneously or separately. Journal of Chromatography 2003, 987:291-309.
37. Neeman G., Blanaru M., Bloch B., Kremer I., Ermilov M., Javitt D.C., Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms nad medication type. American Journal of Psychiatry 2005, 162:1738-1740.
38. Oldendorf W.H. Brain uptake of radio labeled amino acids, amines and hexoses after arterial injection. American Journal of Physiology 1971, 221(6):1629-1639.
39. Perry T.L., Hansen S. Interconversion of serine and glycine is normal in psychotic patients. Psychiatry Research 1985, 15:109-113.
40. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. American Journal of Psychiatry 1999, 156:145-147.
41. Sumiyoshi T., Anil A.E., Jin D., Jayathilake K., Lee M., Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. International Journal of Neuropsychopharmacology 2004, 7(1):1-8.
42. Tomiya M., Fukushima T., Watanabe H., Fukami G., Fujisaki M., Iyo M., Hashimoto K., Mitsuhashi S., Toyóoka T. Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clinica Chimica Acta 2007, 380:186-190.
43. Tsai G., Yang P., Chung L., Lange N., Coyle J.T. d-serine added to antipsychotics for treatment of schizophrenia. Biological Psychiatry 1998, 44(11):1081-1089.
44. Tsai G., Lane H.Y., Yang P., Chong M.Y., Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2004, 55(5):452-456.
45. Tuominen H.J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2005, 72:225-234.
46. Vasanits A., Kutlan D., Sass P., Molnar-Perl I. Retention/quantification properties of the o-phthaldialdehyde-3-mercaptopropionic acid and the o-phthaldialdehyde-N-acetyl-l-cysteine amino acid derivatives in reversed-phase high-performance liquid chromatography. Journal of Chromatography 2000, 870:271-287.
47. Wolosker H., Panizzutti R., De Miranda J. Neurobiology through the looking-glass: d-serine s a new glial-derived transmitter. Neurochemistry International 2002, 41(5):327-332.
48. The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research 1993, World Health Organization, World Health Organization, Geneva.
49. Zhao M., Bada J.L. Determination of α-dialkylamino acids and their enantiomers in geological samples by high-performance liquid chromatography after derivatization with chiral adduct of o-phthaldialdehyde. Journal of Chromatography 1995, 690:55-63.